Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: J Immunol. 2015 Jun 10;195(2):553–563. doi: 10.4049/jimmunol.1500627

Figure 7.

Figure 7

Eos−/− mice develop more severe EAE. (A) Clinical score of EAE in WT and Eos−/− mice. Mice were immunized with MOG/CFA and injected with pertussis toxin on day 0 and 2. (B) Percentage of CD4+, CD4+Foxp3+, and CD4+ MOG-Tetramer+ cells in the CNS on d 12. (C) Percentage of IFN-γ+, IL-17+ and double positive cells in the spleen, draining lymph node, spinal cord and brain of WT and Eos−/− mice on d 12. The cells were harvested, and stimulated with PMA/Ionomycin for 4 h before measurement of cytokine production. (D) Eos staining in the draining lymph node and spinal cord of WT mice with EAE on day 12.